Myocardial perfusion. Chronic ischemic heart disease
Conditions
Interventions
Intervention 1: Intervention group: 30 patients received Nervoxin drug. Intervention 2: Control group: 30 patients who don't recieve any intervention.
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients except patients taking drugs that interact with nevroxin, such as digoxin, warfarin, theophylline, etc. All patients except those with known hepatic and renal failure, patients with coagulation problems and heart disease.
Exclusion criteria
Exclusion criteria: Patients taking drugs that interact with nevroxin, such as digoxin, warfarin, theophylline, etc. People with known hepatic and renal failure, patients with coagulation problems and heart patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 99mTc-MIBI accumulation in liver. Timepoint: 24 hours after receiving the last dose of Nervoxin. Method of measurement: Imaging with gamma camera.;Heart to liver activity ratio. Timepoint: 24 hours after receiving the last dose of Nervoxin. Method of measurement: Imaging with gamma camera. | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference Score in liver clearance of 99mTc-MIBI between control and intervention groups. Timepoint: After myocardial perfusion scan. Method of measurement: Imaging with gamma camera. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZohreh Noaparast
Mazandaran University of Medical Sciences
Outcome results
None listed